New Science and Precision Medicine are closely linked. New Science is a dynamic combination of the best in science and health technology that is projected to drive 61 percent of biopharma revenues until 2026, representing 81% of anticipated industry revenue growth. Precision Medicine has grown with the mapping of the genome to drive the development of personalized treatments for individuals or patient populations. Both work in combination with new, analytical scientific and technological advances to positively impact the biopharma business and help deliver better health outcomes. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care. Accelerated development in cell and gene therapies (CGT) is causing a fundamental shift in the traditional biopharmaceutical business model. Both represent a medical revolution.